Peptide-MHC (major histocompatibility complex) binding assays are essential for neoantigen validation, as they determine whether a predicted neoantigen can effectively bind to MHC molecules and be presented to T cells for immune recognition. These assays help confirm neoantigen immunogenicity before advancing to clinical applications.